These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27481279)

  • 1. Cyclic Systems Distribution Along Similarity Measures: Insights for an Application to Activity Landscape Modeling.
    Pérez-Villanueva J; Méndez-Lucio O; Soria-Arteche O; Izquierdo T; Concepción Lozada M; Gloria-Greimel WA; Medina-Franco JL
    Mol Inform; 2013 Feb; 32(2):179-90. PubMed ID: 27481279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity cliffs and activity cliff generators based on chemotype-related activity landscapes.
    Pérez-Villanueva J; Méndez-Lucio O; Soria-Arteche O; Medina-Franco JL
    Mol Divers; 2015 Nov; 19(4):1021-35. PubMed ID: 26150300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery.
    Naveja JJ; Medina-Franco JL
    Expert Opin Drug Discov; 2015 Oct; 10(10):1059-70. PubMed ID: 26289576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multitarget structure-activity relationships characterized by activity-difference maps and consensus similarity measure.
    Medina-Franco JL; Yongye AB; Pérez-Villanueva J; Houghten RA; Martínez-Mayorga K
    J Chem Inf Model; 2011 Sep; 51(9):2427-39. PubMed ID: 21842860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioactivity landscape modeling: chemoinformatic characterization of structure-activity relationships of compounds tested across multiple targets.
    Waddell J; Medina-Franco JL
    Bioorg Med Chem; 2012 Sep; 20(18):5443-52. PubMed ID: 22178187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CASE plots for the chemotype-based activity and selectivity analysis: a CASE study of cyclooxygenase inhibitors.
    Pérez-Villanueva J; Medina-Franco JL; Méndez-Lucio O; Yoo J; Soria-Arteche O; Izquierdo T; Lozada MC; Castillo R
    Chem Biol Drug Des; 2012 Nov; 80(5):752-62. PubMed ID: 22883137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Activity Cliff Generators of PPAR Ligands Using SAS Maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Mol Inform; 2012 Dec; 31(11-12):837-46. PubMed ID: 27476737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus models of activity landscapes with multiple chemical, conformer, and property representations.
    Yongye AB; Byler K; Santos R; Martínez-Mayorga K; Maggiora GM; Medina-Franco JL
    J Chem Inf Model; 2011 Jun; 51(6):1259-70. PubMed ID: 21609014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationalizing three-dimensional activity landscapes and the influence of molecular representations on landscape topology and the formation of activity cliffs.
    Peltason L; Iyer P; Bajorath J
    J Chem Inf Model; 2010 Jun; 50(6):1021-33. PubMed ID: 20443603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of 3D activity cliffs on the basis of compound binding modes and comparison of 2D and 3D cliffs.
    Hu Y; Bajorath J
    J Chem Inf Model; 2012 Mar; 52(3):670-7. PubMed ID: 22394306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scanning structure-activity relationships with structure-activity similarity and related maps: from consensus activity cliffs to selectivity switches.
    Medina-Franco JL
    J Chem Inf Model; 2012 Oct; 52(10):2485-93. PubMed ID: 22989212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a systematic characterization of the antiprotozoal activity landscape of benzimidazole derivatives.
    Pérez-Villanueva J; Santos R; Hernández-Campos A; Giulianotti MA; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2010 Nov; 18(21):7380-91. PubMed ID: 20888242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional probabilities of activity landscape features for individual compounds.
    Vogt M; Iyer P; Maggiora GM; Bajorath J
    J Chem Inf Model; 2013 Jul; 53(7):1602-12. PubMed ID: 23789585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Representation of multi-target activity landscapes through target pair-based compound encoding in self-organizing maps.
    Iyer P; Bajorath J
    Chem Biol Drug Des; 2011 Nov; 78(5):778-86. PubMed ID: 21895984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular similarity measures.
    Maggiora GM; Shanmugasundaram V
    Methods Mol Biol; 2011; 672():39-100. PubMed ID: 20838964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical landscape analysis with the OpenTox framework.
    Jeliazkova N; Jeliazkov V
    Curr Top Med Chem; 2012; 12(18):1987-2001. PubMed ID: 23110534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMP-Cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs.
    Hu X; Hu Y; Vogt M; Stumpfe D; Bajorath J
    J Chem Inf Model; 2012 May; 52(5):1138-45. PubMed ID: 22489665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning approaches to study the structure-activity relationships of LpxC inhibitors.
    Yu T; Chong LC; Nantasenamat C; Anuwongcharoen N; Piacham T
    EXCLI J; 2023; 22():975-991. PubMed ID: 38023567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Methods for Epigenetic Drug Discovery: A Focus on Activity Landscape Modeling.
    Naveja JJ; Oviedo-Osornio CI; Medina-Franco JL
    Adv Protein Chem Struct Biol; 2018; 113():65-83. PubMed ID: 30149906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.